Discover
JACC Specialty Journals
JACC Asia - Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
JACC Asia - Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
Update: 2023-08-15
Share
Description
Commentary by Dr Jian-Jun Li
Comments
In Channel



